Extracellular superoxide dismutase increased the therapeutic potential of human mesenchymal stromal cells in radiation pulmonary fibrosis

• Published in: Cytotherapy (Oxford, England) England), 2017-05, Vol.19 (5), p.586-602
• Main Authors: Wei, Li, Zhang, Jing, Yang, Zai-Liang, You, Hua
• Format: Article
• Language: English
• Subjects: Advanced Basic Science; Alveolar Epithelial Cells - pathology; Animals; Cell Proliferation; Cell Survival; Collagen - metabolism; Cytokines - metabolism; Disease Models, Animal; extracellular superoxide dismutase; Female; Homeostasis; human umbilical cord–derived mesenchymal stromal cells; Humans; Inflammation - pathology; Lung - pathology; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - metabolism; Mice, Inbred C57BL; Myofibroblasts - pathology; Other; Oxidation-Reduction; oxidative damage; Pulmonary Fibrosis - pathology; Pulmonary Fibrosis - therapy; Radiation Injuries - pathology; Radiation Injuries - therapy; radiation pulmonary fibrosis; reactive oxygen species; Serum; Superoxide Dismutase - metabolism; Umbilical Cord - cytology
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2017.02.359

Abstract Background aims Pulmonary fibrosis induced by irradiation is a significant problem of radiotherapy in cancer patients. Extracellular superoxide dismutase (SOD3) is found to be predominantly and highly expressed in the extracellular matrix of lung and plays a pivotal role against oxidative damage. Early administration of mesenchymal stromal cells (MSCs) has been demonstrated to reduce fibrosis of damaged lung. However, injection of MSCs at a later stage would be involved in fibrosis development. The present study aimed to determine whether injection of human umbilical cord–derived MSCs (UC-MSCs) over-expressing SOD3 at the established fibrosis stage would have beneficial effects in a mice model of radiation pulmonary fibrosis. Methods Herein, pulmonary fibrosis in mice was induced using Cobalt-60 (60 Co) irradiator with 20 Gy, followed by intravenous injection of UC-MSCs, transduced or not to express SOD3 at 2 h (early delivery) and 60 day (late delivery) post-irradiation, respectively. Results Our results demonstrated that the early administration of UC-MSCs could attenuate the microscopic damage, reduce collagen deposition, inhibit (myo)fibroblast proliferation, reduce inflammatory cell infiltration, protect alveolar type II (AE2) cell injury, prevent oxidative stress and increase antioxidant status, and reduce pro-fibrotic cytokine level in serum. Furthermore, the early treatment with SOD3-infected UC-MSCs resulted in better improvement. However, we failed to observe the therapeutic effects of UC-MSCs, transduced to express SOD3, during established fibrosis. Conclusion Altogether, our results demonstrated that the early treatment with UC-MSCs alone significantly reduced radiation pulmonary fibrosis in mice through paracrine effects, with further improvement by administration of SOD3-infected UC-MSCs, suggesting that SOD3-infected UC-MSCs may be a potential cell-based gene therapy to treat clinical radiation pulmonary fibrosis.